EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas

Justin Z Wang, Vikas Patil, Jeff Liu, Helin Dogan, Ghazaleh Tabatabai, Leeor S Yefet, Felix Behling, Elgin Hoffman, Severa Bunda, Rebecca Yakubov, Ramneet Kaloti, Sebastian Brandner und 12 weitere

Acta Neuropathologica · 2023-07 · 146 (1) · 145-162

DOI: 10.1007/s00401-023-02571-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Neuropathologica, online erschienen am 24.04.2023. Verfasst von Justin Z Wang und 23 weiteren Autor:innen. Beteiligte Einrichtung: MacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Meningioma, Meningeal Neoplasms. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Canadian Institutes of Health Research, American Association of Neurological Surgeons.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Homozygous deletion of CDKN2A/B was recently incorporated into the World Health Organization classification for grade 3 meningiomas. While this marker is overall rare in meningiomas, its relationship to other CDKN2A alterations on a transcriptomic, epigenomic, and copy number level has not yet been determined. We therefore utilized multidimensional molecular data of 1577 meningioma samples from 6 independent cohorts enriched for clinically aggressive meningiomas to comprehensively interrogate the spectrum of CDKN2A alterations through DNA methylation, copy number variation, transcriptomics, and proteomics using an integrated molecular approach. Homozygous CDKN2A/B deletions were identified in only 7.1% of cases but were associated with significantly poorer outcomes compared to tumors without these deletions. Heterozygous CDKN2A/B deletions were identified in 2.6% of cases and had similarly poor outcomes as those with homozygous deletions. Among tumors with intact CDKN2A/B (without a homozygous or heterozygous deletion), we found a distinct difference in outcome based on mRNA expression of CDKN2A, with meningiomas that had elevated mRNA expression (CDKN2A high ) having a significantly shorter time to recurrence. The expression of CDKN2A was independently prognostic after accounting for copy number loss and consistently increased with WHO grade and more aggressive molecular and methylation groups irrespective of cohort. Despite the discordant and mutually exclusive status of the CDKN2A gene in these groups, both CDKN2A high meningiomas and meningiomas with CDKN2A deletions were enriched for similar cell cycle pathways but at different checkpoints. High mRNA expression of CDKN2A was also associated with gene hypermethylation, Rb-deficiency, and lack of response to CDK inhibition. p16 immunohistochemistry could not reliably differentiate between meningiomas with and without CDKN2A deletions but appeared to correlate better with mRNA expression. These findings support the role of CDKN2A mRNA expression as a biomarker of clinically aggressive meningiomas with potential therapeutic implications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeningiomaMeningeal NeoplasmsHumansGenes, p16Cyclin-Dependent Kinase Inhibitor p16TranscriptomeDNA Copy Number VariationsHomozygoteSequence Deletion

Stichwörter der Autor:innen

CDK inhibitorCDKN2ACopy number alterationsMeningiomasMultiomicRetinoblastoma

Substanzen

Cyclin-Dependent Kinase Inhibitor p16CDKN2A protein, human

Autor:innen und Institutionen

  • MacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, ON, Canada.
  • Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, ON, Canada.
  • Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Department of Neuropathology, University Hospital Heidelberg (DKFZ), Heidelberg, Germany.
  • Department of Neurosurgery, Center for Neuro-Oncology, Comprehensive Cancer Center, Eberhard Karls University Tübingen, Tübingen, Germany.
  • German Cancer Consortium (DKTK), DKFZ Partner Site Tübingen, Tübingen, Germany.

Förderung

  • NCI NIH HHS
  • Canadian Institutes of Health Research
  • American Association of Neurological Surgeons

Zitieren

APA

Wang, J. Z., Patil, V., Liu, J., Dogan, H., Tabatabai, G., Yefet, L. S., Behling, F., Hoffman, E., Bunda, S., Yakubov, R., Kaloti, R., Brandner, S., Gao, A., Cohen-Gadol, A., Barnholtz-Sloan, J., Skardelly, M., Tatagiba, M., Raleigh, D. R., Sahm, F., …, & Zadeh, G. (2023). Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas. Acta Neuropathologica, 146(1), 145-162. https://doi.org/10.1007/s00401-023-02571-3

Vancouver

Wang JZ, Patil V, Liu J, Dogan H, Tabatabai G, Yefet LS, et al. Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas. Acta Neuropathologica. 2023;146(1):145-162. doi:10.1007/s00401-023-02571-3

BibTeX
@article{Wang2023,
  author = {Wang, Justin Z and Patil, Vikas and Liu, Jeff and Dogan, Helin and Tabatabai, Ghazaleh and Yefet, Leeor S and Behling, Felix and Hoffman, Elgin and Bunda, Severa and Yakubov, Rebecca and Kaloti, Ramneet and Brandner, Sebastian and Gao, Andrew and Cohen-Gadol, Aaron and Barnholtz-Sloan, Jill and Skardelly, Marco and Tatagiba, Marcos and Raleigh, David R and Sahm, Felix and Boutros, Paul C and Aldape, Kenneth and International Consortium on Meningiomas (ICOM), International Consortium on Meningiomas (ICOM) and Nassiri, Farshad and Zadeh, Gelareh},
  title = {Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas},
  journal = {Acta Neuropathologica},
  year = {2023},
  volume = {146},
  number = {1},
  pages = {145--162},
  doi = {10.1007/s00401-023-02571-3}
}
Kostenlos starten →